CTHRC1 and pulmonary fibrosis: These studies highlight CTHRC1-positive myofibroblasts as critical contributors to fibrogenesis and suggest that they are targets of therapeutic drugs, such as pirfenidone or bexotegrast, that can mitigate lung fibrosis.